Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.
Other equities analysts have also recently issued reports about the company. Needham & Company LLC boosted their price target on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday. Morgan Stanley lifted their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an "overweight" rating in a research report on Thursday. Weiss Ratings raised shares of Arcutis Biotherapeutics from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Thursday. Finally, Guggenheim upped their target price on shares of Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a "buy" rating in a report on Thursday. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $35.57.
Read Our Latest Stock Analysis on Arcutis Biotherapeutics
Arcutis Biotherapeutics Trading Down 4.3%
Shares of ARQT opened at $25.29 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.92 and a quick ratio of 2.46. Arcutis Biotherapeutics has a 1-year low of $13.69 and a 1-year high of $31.77. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of 120.43 and a beta of 1.49. The firm has a 50 day simple moving average of $26.05 and a 200-day simple moving average of $24.69.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.05. The firm had revenue of $129.86 million for the quarter, compared to analyst estimates of $118.85 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. Equities analysts forecast that Arcutis Biotherapeutics will post 0.16 EPS for the current fiscal year.
Insiders Place Their Bets
In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 4,096 shares of the business's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.41, for a total value of $99,983.36. Following the completion of the transaction, the director directly owned 38,378 shares in the company, valued at approximately $936,806.98. The trade was a 9.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Todd Watanabe sold 4,375 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.12, for a total value of $114,275.00. Following the sale, the insider owned 717,203 shares in the company, valued at $18,733,342.36. This trade represents a 0.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 16,894 shares of company stock valued at $422,044. Insiders own 9.40% of the company's stock.
Institutional Trading of Arcutis Biotherapeutics
A number of hedge funds have recently added to or reduced their stakes in the business. Citizens Financial Group Inc. RI purchased a new stake in Arcutis Biotherapeutics in the 2nd quarter valued at about $922,000. BlackRock Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter worth approximately $276,502,000. Deutsche Bank AG acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter worth approximately $10,034,000. Persistent Asset Partners Ltd purchased a new stake in Arcutis Biotherapeutics in the second quarter valued at approximately $227,000. Finally, Bank of New York Mellon Corp purchased a new stake in Arcutis Biotherapeutics in the second quarter valued at approximately $8,655,000.
Key Arcutis Biotherapeutics News
Here are the key news stories impacting Arcutis Biotherapeutics this week:
- Positive Sentiment: Strong second-quarter performance: Arcutis reported adjusted EPS of $0.11, exceeding estimates of $0.06–$0.09 and improving from a $0.13 loss a year earlier. Revenue rose 59% year over year to $129.9 million, beating the $118.9 million consensus estimate. Arcutis Q2 Earnings and Revenues Surpass Estimates
- Positive Sentiment: Raised sales outlook and expanding ZORYVE opportunity: Management increased 2026 net product-sales guidance to $525 million–$540 million. ZORYVE also gained an expanded pediatric plaque-psoriasis approval, while the FDA accepted an application for use in infants with atopic dermatitis. Arcutis Second-Quarter 2026 Financial Results
- Positive Sentiment: Analyst support remains favorable: Needham raised its price target from $36 to $40 and reiterated a Buy rating. HC Wainwright’s 2027 estimates project quarterly EPS rising from $0.08 in the first quarter to $0.48 in the fourth quarter, suggesting expectations for continued earnings growth. Benzinga analyst report
- Neutral Sentiment: Commercial leadership changes: Arcutis announced key changes to its commercial leadership team. The move could support execution, but investors may initially view management transitions as an operational uncertainty. Arcutis Announces Key Commercial Leadership Changes
- Neutral Sentiment: Insider selling was limited and prearranged: Three executives sold a combined 6,560 shares to cover tax withholding on vested equity awards under Rule 10b5-1 plans, reducing the bearish significance of the transactions.
About Arcutis Biotherapeutics
(
Get Free Report)
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Arcutis Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcutis Biotherapeutics wasn't on the list.
While Arcutis Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
